Can Dose Reduction to One Parotid Gland Prevent Xerostomia? - A Feasibility Study for Locally Advanced Head and Neck Cancer Patients Treated with Intensity-modulated Radiotherapy

Clinical Oncology

Volumn 18, Issue 6, 2006, Pages 497-504

  Anand, A K ^a   Jain, J ^a   Negi, P S ^a   Chaudhoory, A R ^a   Sinha, S N ^a   Choudhury, P S ^a   Kumar, R ^a   Munjal, R K ^a  

^a RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

Author keywords

Head and neck; IMRT; xerostomia prevention

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; NASOPHARYNX CANCER; OROPHARYNX CANCER; PAROTID GLAND; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION DOSE; SALIVARY GLAND; SALIVARY GLAND DISEASE; SYMPTOM; TONGUE CANCER; TREATMENT PLANNING; XEROSTOMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAROTID GLAND; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; XEROSTOMIA;

EID: 33745662433     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.04.014     Document Type: Article

References (24)

1. Beeken L., and Calman F. A return to normal eating after curative treatment for oral cancer. Long term prospects. Oral Oncol 6 (1994) 387-392
2. Bjordal K., Kaasa S., and Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 28 (1994) 847-856
3. Cooper J.S., Fu K., Marks J., et al. Late effect of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 31 (1995) 1141-1164
4. Jensen A.B., Hanse O., Jorgensen K., et al. Influence of late side effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol 33 (1994) 487-491
5. Drejzen S., Brown L.R., Daly T.E., and Drane J.F. Prevention of xerostomia related dental caries in irradiated cancer patients. J Dent Res 56 (1977) 99-104
6. Chao K.S.C., Majhail N., Huang C.J., et al. Intensity modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma. A comparison with conventional techniques. Radiother Oncol 61 (2001) 275-280
7. Wu Q., Mohan R., Morris M., et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-neck squamous cell carcinoma. 1: Dosimetric results. Int J Radiat Oncol Biol Phys 56 (2003) 573-585
8. Chao K.S.C., Ozyigit G., and Thorsdad W.L. Toxicity profile of intensity modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Semin Oncol 30 suppl 18 (2003) 101-108
9. Van Dieren E.B., Nowak P.J.C.M., and Wijers O.B. Beam intensity modulated using tissue compensators or dynamic multileaf collimation in three-dimensional conformal radiotherapy of primary cancers of the oropharynx and larynx, including the elective neck. Int J Radiat Oncol Biol Phys 47 (2000) 1299-1309
10. Dawson L.A., Anzai Y., Marsh L., et al. Pattern of local-regional recurrence following parotid-sparing conformal and segmental intensity modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 46 (2000) 1117-1126
11. Franzen I., Funegard U., Ericson T., et al. Parotid gland function during and following radiation therapy of malignancies in the head and neck: a consecutive study of salivary flow and patient discomfort. Eur J Cancer 28 (1992) 457-462
12. Eisbruch A., Ten Haken R.K., Kim H.M., Marsh L.H., and Ship J.A. Dose, volume and function relationships in parotid salivary glands following conformal and intensity modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45 (1999) 577-587
13. Greene F.L. Head and neck sites (Part II). In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual. 6th edn (2002), Springer, Berlin 17-87
14. Amosson C.M., Teh B.S., Van T.J., et al. Dosimetric predicators of xerostomia for head and neck cancer patients treated with SMART (simultaneous modulated accelerated radiation therapy). Int J Radiat Oncol Biol Phys 56 (2003) 136-144
15. Eisbruch A., Rhodus N., Rosenthal D., et al. How should we measure and report radiotherapy-induced xerostomia. Semin Radiat Oncol 13 (2003) 226-234
16. Epstein J.B., Emerton S., Kolbinson D.A., et al. Quality of life and oral function following radiation therapy for head and neck cancer. Head Neck 21 (1999) 1-11
17. Hanrison Z.B., Zelefsky M.J., Pfister D.G., et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of tongue. Head Neck 19 (1997) 169-175
18. Eisbruch A., Kim H.M., Terrell J.E., et al. Xerostomia and its predictors following parotid sparing irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 695-704
19. Mira J.G., Wescott W.B., Starcke E.N., et al. Some factors influencing salivary function when treating with radiotherapy. Int J Radiat Oncol Biol Phys 7 (1981) 535-541
20. Liem L.H., Valdes Olmos R.A., Balm A.J.M., et al. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumors. Eur J Nucl Med 23 (1996) 1485-1490
21. Wang S.L., Zhao Z.T., Li J., et al. Investigation of the clinical value of total saliva flow rates. Arch Oral Biol 43 (1998) 39-43
22. Ship J.A., Fox P.C., and Baum B.J. How much saliva is enough? "Normal" function defined. J Am Dent Assoc 122 (1991) 63-69
23. Le Veque F.G., Montgomery M., Potter D., et al. A multicentre, randomized double blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation induced xerostomia in head and neck cancer patients. J Clin Oncol 11 (1993) 1124-1131
24. Valdez I.H., Wolff A., Atkinson J.C., et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary gland dysfunction. Cancer 71 (1993) 1848-1851